Naglazyme is a medication that is used to treat patients with mucopolysaccharidosis type VI (MPS VI), also known as Maroteaux-Lamy syndrome. This rare genetic disorder causes a deficiency in the enzyme arylsulfatase B, leading to the accumulation of glycosaminoglycans in the body’s tissues and organs.
Naglazyme works by replacing the missing enzyme in patients with MPS VI, helping to break down and remove the excess glycosaminoglycans from the body. This can help improve symptoms such as joint stiffness, respiratory issues, and organ damage associated with the condition.
It is important to follow the dosing schedule prescribed by your healthcare provider when taking Naglazyme. This medication is typically administered through intravenous infusion, and the frequency and dosage will be determined based on your individual needs and response to treatment.
As with any medication, Naglazyme may cause side effects in some patients. Common side effects may include fever, chills, headache, and nausea. It is important to report any unusual or severe side effects to your healthcare provider promptly.
It is also important to discuss any other medications or supplements you are taking with your healthcare provider before starting Naglazyme, as interactions may occur.
Overall, Naglazyme has been shown to be an effective treatment for patients with MPS VI, helping to improve quality of life and slow the progression of the disease. If you have been diagnosed with MPS VI, talk to your healthcare provider to see if Naglazyme may be a suitable treatment option for you.
EN 
ES 
FR 
PT 
ZH